GENINCODE PLC Logo

GENINCODE PLC

Specializes in genetic risk assessment and prediction of cardiovascular disease.

GENI | IL

Overview

Corporate Details

ISIN(s):
GB00BL97B504
LEI:
213800UX6TE7K65O2892
Country:
United Kingdom
Address:
ONE, ST. PETERS SQUARE, M2 3DE MANCHESTER

Description

GENINCODE PLC specializes in the genetic risk assessment and prediction of cardiovascular disease (CVD). The company develops and commercializes clinical genetic tests that combine genomic data with clinical algorithms and artificial intelligence (AI). These advanced risk assessment tools provide physicians with a predictive analysis of a patient's health, enabling personalized prevention and treatment strategies for CVD. The company's technology is founded on over 15 years of research and development in cardiovascular genomics, aiming to improve patient outcomes by identifying at-risk individuals before the onset of disease.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-08 14:55
Holding(s) in Company
English 22.2 KB
2025-12-04 08:45
Collaboration with Thermo Fisher
English 20.2 KB
2025-12-03 08:40
Approval of CARDIO inCode-score in New York state
English 19.0 KB
2025-10-13 17:21
Holding(s) in Company
English 22.1 KB
2025-09-24 18:58
Holding(s) in Company
English 23.6 KB
2025-09-17 11:42
Stmnt re Share Price Movement
English 18.0 KB
2025-08-26 08:00
Trading update
English 15.7 KB
2025-07-07 08:00
De Novo Update – FDA Supervisory Review
English 18.4 KB
2025-06-30 12:42
Result of AGM
English 11.1 KB
2025-06-04 08:00
Final Results
English 606.0 KB
2025-05-16 08:00
Notice of Results
English 18.4 KB
2025-03-26 08:45
Grant of Share Options & PDMR Dealings
English 57.5 KB
2025-03-06 15:24
Holding(s) in Company
English 21.9 KB
2025-03-05 16:02
Holding(s) in Company
English 22.0 KB
2025-03-04 14:16
Holding(s) in Company
English 21.9 KB

Automate Your Workflow. Get a real-time feed of all GENINCODE PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for GENINCODE PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for GENINCODE PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Alpha Tau Medical Ltd. Logo
Clinical-stage oncology firm developing alpha radiation therapy for solid tumors.
United States of America
DRTS
Alteogen Inc. Logo
Biopharmaceutical firm developing biologics with proprietary drug delivery technologies.
South Korea
196170
AlzeCure Pharma Logo
Develops therapies for severe diseases, focusing on Alzheimer's and pain.
Sweden
ALZCUR
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapeutics for inflammatory diseases.
United States of America
ANAB
AngioLab, Inc. Logo
Develops angiogenesis inhibitors for pharmaceuticals and health functional foods.
South Korea
251280
Anixa Biosciences Inc Logo
A clinical-stage biotech developing therapies and vaccines to treat and prevent cancer.
United States of America
ANIX
Annovis Bio, Inc. Logo
A clinical-stage drug platform company developing therapies for neurodegenerative diseases.
United States of America
ANVS
Develops and manufactures DNA-based technologies for genetic medicine and diagnostics.
United States of America
APDN
Aprea Therapeutics, Inc. Logo
Clinical-stage biopharma developing cancer therapeutics via synthetic lethality.
United States of America
APRE
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases, oncology, and rare diseases.
South Korea
397030

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.